2245953-10-8
2245953-10-8
Chemical Structure
Dazodalibep
Synonym(s): MEDI 4920; VIB 4920
- CAS No.: 2245953-10-8
- Formula:N/A
- Molecular Weight:(87.82 kDa)
IUPAC Name: 4-bromothieno[2,3-b]pyridine
SMILES: [Dazodalibep]
Biological Activity: Dazodalibep (MEDI 4920) is a non-antibody fusion protein that acts as a CD40 ligand (CD40L) antagonist. Dazodalibep is used in the research of rheumatoid arthritis and Sjögren's syndrome[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Dazodalibep | 99% | Dazodalibep (MEDI 4920) is a non-antibody fusion protein that acts as a CD40 ligand (CD40L) antagonist. Dazodalibep is used in the research of rheumatoid arthritis and Sjögren's syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Bustos AH, et al. Citrullinated peptides as drug candidates for rheumatoid arthritis. Frontiers in immunology. 2025;16:1648913.
- [2]. Aung T, et al. Bridging the Gap in Sjögren's Disease: A Comprehensive Review of Unmet Needs, Diagnostic Challenges, and Emerging Therapeutic Strategies. Cureus. 2026 Jul;18(7):e113186.
- [3]. Palla P, et al. Infections in Sjögren's disease: a clinical concern or not?. Clinical and experimental rheumatology. 2024 Dec;42(12):2531-2541.
